Australia's largest stock trading and investment forum Australia's #1 stock forum

IPD

1.85%

5.3¢ impedimed limited

Ann: Follow up to NCCN Guidelines for Breast Cancer ASX Release, page-43

First 43 Last

Share
Profile

Follow
jsonm

112 Posts.

143

25/03/23

13:53

Post #: 66957357
Share

Originally posted by Acclivity: ↑

Hi Stock holders, pg 93 to 100
Survivorship_1.2023.pdf
Pg 94
• If possible, pretreatment limb measurement of both sides should be performed as a baseline for survivors with treatment-related orindividual risk factors, preferably by a trained lymphedema specialist.• Early detection/diagnosis and early referral are key for optimal lymphedema management because stages 0 and 1 are reversible, whereasstages 2 and 3 are less responsive to treatment. Therefore, survivors at risk for lymphedema should be regularly screened for lymphedemaby symptom assessment, clinical exam, and, if available, bioimpedance spectroscopy. Patients should be educated about early symptomsand signs of lymphedema including fullness, tightness, heaviness, and pain.
pg 96
• Perform clinical examination,which may include, but is notlimited to:Range of motionMuscle performanceCirculationSensationHemodynamic functioningFunctional mobilityIf available, obtain objectivemeasurements to identifyearly signs of lymphedema;tools may includebioimpedance spectroscopy
pg 97
FOOTNOTES FOR LYMPHEDEMA TREATMENT (SLYMPH-3)
i Certified lymphedema therapists can be located using the following resource: https://www.clt-lana.org/therapists. NCCN recommends attention to evidence-basedpractice and specialized training for lymphedema management.
pg 100
Survivors should undergo baseline and periodic evaluation for development or exacerbation of lymphedema.Regards
Acclivity

Expand

Brilliant news and an absolute watershed moment in IPD's history. Congratulations to fellow holders.

IPD Price at posting: 5.9¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

HotCopper Highlights: Your most watched stocks for Week 46, 2024

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

First 43 Last

Add IPD (ASX) to my watchlist

(20min delay)
Last 5.3¢		Change -0.001(1.85%)		Mkt cap ! $107.2M

Open	High	Low	Value	Volume
5.4¢	5.4¢	5.2¢	$68.49K	1.292M

Buyers (Bids)

No.	Vol.	Price($)
1	400000	5.2¢

Sellers (Offers)

Price($)	Vol.	No.
5.3¢	14094	1

View Market Depth

No.	Vol.	Price($)
1	400000	0.052
1	500000	0.051
5	190000	0.050
1	61000	0.049
1	27812	0.048

Price($)	Vol.	No.
0.053	14094	1
0.054	100000	1
0.055	332498	2
0.056	250000	1
0.058	7842	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

IPD (ASX) Chart

Ann: Follow up to NCCN Guidelines for Breast Cancer ASX Release, page-43

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Follow up to NCCN Guidelines for Breast Cancer ASX Release, page-43

Top Stories

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News